Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naive and Switch Scenarios in HIV-Infected Patients
Por:
Saumoy, M, Sanchez-Quesada, JL, Ordonez-Llanos, J, Podzamczer, D
Publicada:
1 ago 2021
Resumen:
In this study, we aim to explore the effects on lipids of integrase strand transfer inhibitors (INSTIs) in naive and switch randomised controlled trials, and compare them with protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). We reviewed phase 3/4 randomised clinical trials in the Cochrane and PubMed databases that compare an INSTI with a boosted PI, an NNRTI, or another INSTI plus one or two nucleoside/nucleotide reverse transcriptase inhibitors (NtRTIs) in naive patients and switching strategies in HIV-infected patients. We reported the baseline plasma concentration of total cholesterol (TC), low and high-density lipoprotein cholesterol (LDL-c, HDL-c), triglycerides (TG), and the TC/HDL-c ratio, as well as the change at weeks 48 and 96, when available. In naive HIV-infected patients, raltegravir (RAL) and dolutegravir (DTG) have a more favourable lipid profile compared with NNRTI and boosted PI. Elvitegravir (EVG/c) has a superior lipid profile compared with efavirenz and is similar to that observed with ritonavir-boosted atazanavir except in TG, which increases less with EVG/c. In naive patients, RAL, DTG, and bictegravir (BIC) produce a similar, slight increase in lipids. In switching trials, the regimen change based on a boosted PI or efavirenz to RAL, DTG, or BIC is associated with clinically significant decreases in lipids that are minor when the change is executed on EVG/c. No changes were observed in lipids by switching trials between INSTIs. In summary, RAL, DTG, and BIC have superior lipid profiles compared with boosted-PI, efavirenz, and EVG/c, in studies conducted in naive participants, and they are associated with a clinically significant decrease in lipoproteins by switching studies.
Filiaciones:
Saumoy, M:
Bellvitge Inst Biomed Res, Barcelona 08907, Spain
Bellvitge Univ Hosp, Infect Dis Dept, HIV & STD Unit, C Feixa Llarga S-N, Barcelona 08907, Spain
Sanchez-Quesada, JL:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08041, Spain
Ordonez-Llanos, J:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08041, Spain
Fdn Biochem & Mol Pathol, Barcelona 08041, Spain
Podzamczer, D:
Bellvitge Inst Biomed Res, Barcelona 08907, Spain
Bellvitge Univ Hosp, Infect Dis Dept, HIV & STD Unit, C Feixa Llarga S-N, Barcelona 08907, Spain
Green Published, gold
|